IOTA NanoSolutions
IOTANANO is a company focused on advancing glycobiology, glycoproteomics, and biotechnological research. They develop and provide a wide range of laboratory reagents, assays, and tools for studying carbohydrates, glycoproteins, and related biological processes. Their mission is to facilitate innovative research and therapeutic development through cutting-edge technologies and comprehensive databases.
Industries
Nr. of Employees
small (1-50)
IOTA NanoSolutions
1234 Research Ave, Science City, Country
Patents
Services
Publication of in‑depth articles and reviews on glycobiology, glycosylation mechanisms, glycoproteomics methods, and assay evaluation.
Aggregation of supplier reagent listings and comparative notes on assay kits, antibodies, and reagents to support reagent selection and procurement decisions.
Analysis and recommendations for hybrid risk‑assessment methods addressing biosecurity and safety challenges at the intersection of artificial intelligence and biotechnology.
Publication of in‑depth articles and reviews on glycobiology, glycosylation mechanisms, glycoproteomics methods, and assay evaluation.
Aggregation of supplier reagent listings and comparative notes on assay kits, antibodies, and reagents to support reagent selection and procurement decisions.
Analysis and recommendations for hybrid risk‑assessment methods addressing biosecurity and safety challenges at the intersection of artificial intelligence and biotechnology.
Expertise Areas
- Glycobiology and glycoproteomics
- Glycoengineering for biologics
- Glycan profiling and mapping
- Immunoassay development and validation
Key Technologies
- Liquid chromatography–mass spectrometry (LC‑MS)
- MALDI and electrospray ionization mass spectrometry
- Glycan microarrays
- High‑performance liquid chromatography (HPLC)
News & Updates
A comprehensive analysis of the potential risks and evaluation frameworks for AI and biotech convergence.
An overview of how glycobiology is transforming personalized medicine.
A comprehensive analysis of the potential risks and evaluation frameworks for AI and biotech convergence.
An overview of how glycobiology is transforming personalized medicine.